CN115348957B - 用于治疗与sting活性有关的疾病的化合物和组合物 - Google Patents

用于治疗与sting活性有关的疾病的化合物和组合物

Info

Publication number
CN115348957B
CN115348957B CN202080097901.0A CN202080097901A CN115348957B CN 115348957 B CN115348957 B CN 115348957B CN 202080097901 A CN202080097901 A CN 202080097901A CN 115348957 B CN115348957 B CN 115348957B
Authority
CN
China
Prior art keywords
independently selected
alkyl
compound
optionally substituted
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080097901.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN115348957A (zh
Inventor
H·M·塞德尔
W·R·劳世
S·范卡彻曼
J·卡茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma AG
Original Assignee
Novartis Pharma AG
Afumdeyou Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma AG, Afumdeyou Co ltd filed Critical Novartis Pharma AG
Priority to CN202511145327.2A priority Critical patent/CN120965654A/zh
Publication of CN115348957A publication Critical patent/CN115348957A/zh
Application granted granted Critical
Publication of CN115348957B publication Critical patent/CN115348957B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080097901.0A 2019-12-31 2020-12-30 用于治疗与sting活性有关的疾病的化合物和组合物 Active CN115348957B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202511145327.2A CN120965654A (zh) 2019-12-31 2020-12-30 用于治疗与sting活性有关的疾病的化合物和组合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962955839P 2019-12-31 2019-12-31
US62/955,839 2019-12-31
US202063090538P 2020-10-12 2020-10-12
US63/090,538 2020-10-12
PCT/US2020/067483 WO2021138434A1 (en) 2019-12-31 2020-12-30 Compounds and compositions for treating conditions associated with sting activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202511145327.2A Division CN120965654A (zh) 2019-12-31 2020-12-30 用于治疗与sting活性有关的疾病的化合物和组合物

Publications (2)

Publication Number Publication Date
CN115348957A CN115348957A (zh) 2022-11-15
CN115348957B true CN115348957B (zh) 2025-11-25

Family

ID=74206237

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080097901.0A Active CN115348957B (zh) 2019-12-31 2020-12-30 用于治疗与sting活性有关的疾病的化合物和组合物
CN202511145327.2A Pending CN120965654A (zh) 2019-12-31 2020-12-30 用于治疗与sting活性有关的疾病的化合物和组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202511145327.2A Pending CN120965654A (zh) 2019-12-31 2020-12-30 用于治疗与sting活性有关的疾病的化合物和组合物

Country Status (8)

Country Link
US (1) US20230127839A1 (https=)
EP (1) EP4085051A1 (https=)
JP (1) JP7756643B2 (https=)
CN (2) CN115348957B (https=)
PY (1) PY2089159A (https=)
TW (1) TW202136239A (https=)
UY (1) UY39006A (https=)
WO (1) WO2021138434A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120004785A (zh) 2018-07-03 2025-05-16 诺华制药股份有限公司 用于治疗与sting活性有关的疾病的化合物和组合物
EP4267128A1 (en) 2020-12-22 2023-11-01 IFM Due, Inc. Methods of treating cancer
US20240060982A1 (en) 2020-12-22 2024-02-22 Ifm Due, Inc. Methods of treating cancer
JP2024500874A (ja) 2020-12-22 2024-01-10 アイエフエム デュー インコーポレイテッド がんを処置する方法
EP4267129A1 (en) 2020-12-22 2023-11-01 IFM Due, Inc. Methods of treating cancer
EP4274824A1 (en) 2021-01-08 2023-11-15 IFM Due, Inc. Heterobicyclic compounds having an urea or analogue and their compositions for treating conditions associated with sting activity
JP2024502470A (ja) * 2021-01-08 2024-01-19 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
CN116981668A (zh) * 2021-04-09 2023-10-31 百济神州(北京)生物科技有限公司 制备bcl-2抑制剂的中间体的方法
IL310724A (en) 2021-08-10 2024-04-01 Ifm Due Inc COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH STING ACTIVITY
WO2024064358A1 (en) 2022-09-23 2024-03-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN117756698A (zh) * 2022-12-16 2024-03-26 中国药科大学 脲类化合物及其作为sting抑制剂的医药用途
CN116023321B (zh) * 2022-12-30 2024-11-29 中国药科大学 Sting抑制剂前药及其医药用途
CN120794982A (zh) * 2024-05-14 2025-10-17 中国药科大学 吡唑类sting抑制剂及其医药用途
CN120794957A (zh) * 2024-05-14 2025-10-17 中国药科大学 苯并含氮杂环类sting抑制剂及其医药用途
WO2026023667A1 (ja) * 2024-07-25 2026-01-29 カルナバイオサイエンス株式会社 フェニルピペラジン誘導体

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020191227A1 (en) * 2019-03-20 2020-09-24 Cornell University Methods for controlling prostaglandin-mediated biological processes
CN117320708A (zh) * 2020-12-22 2023-12-29 艾福姆德尤股份有限公司 治疗癌症的方法
CN117412745A (zh) * 2020-12-22 2024-01-16 艾福姆德尤股份有限公司 治疗癌症的方法
CN117425475A (zh) * 2020-12-22 2024-01-19 艾福姆德尤股份有限公司 治疗癌症的方法
CN117597117A (zh) * 2020-12-22 2024-02-23 艾福姆德尤股份有限公司 治疗癌症的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5783558A (en) * 1980-11-13 1982-05-25 Asahi Chem Ind Co Ltd Novel organic compound and its preparation
JPS5783557A (en) * 1980-11-14 1982-05-25 Asahi Chem Ind Co Ltd Novel azomethine compound and its preparation
US20120046290A1 (en) * 1997-12-22 2012-02-23 Jacques Dumas Inhibition of p38 kinase activity using substituted heterocyclic ureas
BR0212841A (pt) 2001-09-26 2004-08-03 Pharmacia Italia Spa Derivado ativo de aminoindazole como inibidores de cinase, processo para sua preparação e composições farmacêuticas que os contém
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
DE102005038947A1 (de) 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
JP2013545740A (ja) 2010-11-10 2013-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング バニロイド受容体リガンドとしての置換された複素芳香族カルボキサミド誘導体および尿素誘導体
US8497285B2 (en) 2010-12-03 2013-07-30 The Trustees Of The University Of Pennsylvania Therapy of autoimmune colitis using a TIP60 inhibitor
CN102516153B (zh) 2011-12-14 2014-03-12 南京工业大学 5-氟吲哚-2-酮-3-脲类化合物及其制备方法和应用
CA2914815A1 (en) 2013-06-11 2014-12-18 Kala Pharmaceuticals, Inc. Urea derivatives and uses thereof
CA2927009C (en) 2013-10-21 2019-04-23 Drexel University Use of sting agonists to treat chronic hepatitis b virus infection
CN107417478B (zh) 2017-06-05 2020-05-05 南京师范大学 一种催化氧化羰基化合成不对称二取代脲的方法
EP3556362A1 (en) 2018-04-16 2019-10-23 Ecole Polytechnique Federale De Lausanne (Epfl) Sting inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020191227A1 (en) * 2019-03-20 2020-09-24 Cornell University Methods for controlling prostaglandin-mediated biological processes
CN117320708A (zh) * 2020-12-22 2023-12-29 艾福姆德尤股份有限公司 治疗癌症的方法
CN117412745A (zh) * 2020-12-22 2024-01-16 艾福姆德尤股份有限公司 治疗癌症的方法
CN117425475A (zh) * 2020-12-22 2024-01-19 艾福姆德尤股份有限公司 治疗癌症的方法
CN117597117A (zh) * 2020-12-22 2024-02-23 艾福姆德尤股份有限公司 治疗癌症的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Synthesis and antiproliferative activity of 3-amino-N-phenyl-1H-indazole-1-carboxamides;Demetrio Raffa，等;《European Journal of Medicinal Chemistry》;第44卷;165-178 *

Also Published As

Publication number Publication date
TW202136239A (zh) 2021-10-01
UY39006A (es) 2021-07-30
JP2023509422A (ja) 2023-03-08
CN115348957A (zh) 2022-11-15
WO2021138434A1 (en) 2021-07-08
JP7756643B2 (ja) 2025-10-20
EP4085051A1 (en) 2022-11-09
PY2089159A (es) 2022-05-11
US20230127839A1 (en) 2023-04-27
CN120965654A (zh) 2025-11-18

Similar Documents

Publication Publication Date Title
CN115348957B (zh) 用于治疗与sting活性有关的疾病的化合物和组合物
CN112823036B (zh) 用于治疗与sting活性有关的疾病的化合物和组合物
CN112823151B (zh) 用于治疗与sting活性有关的疾病的化合物和组合物
TWI873145B (zh) 用於治療與sting活性相關之病狀的化合物及組合物
CN113382772B (zh) 用于治疗与sting活性有关的疾病的化合物和组合物
CN115279770A (zh) 用于治疗与sting活性有关的疾病的化合物和组合物
CN116528862A (zh) 用于治疗与sting活性有关的疾病的化合物和组合物
CN116157394A (zh) 用于治疗与sting活性有关的疾病的化合物和组合物
TW202126622A (zh) 用於治療與ｓｔｉｎｇ活性相關之病狀的化合物及組合物
CN117529475A (zh) 用于治疗与sting活性有关的疾病的含脲或类似物的杂双环化合物及其化合物
CN117561253A (zh) 用于治疗与sting活性有关的病症的化合物和组合物
CN116261452A (zh) 用于治疗与sting活性有关的疾病的化合物和组合物
CN117222634A (zh) 用于治疗与sting活性有关的疾病的化合物和组合物
CN117480169A (zh) 用于治疗与sting活性有关的疾病的化合物和组合物
WO2023137034A1 (en) Compounds and compositions for treating conditions associated with sting activity
WO2024151919A1 (en) Compounds and compositions for treating conditions associated with sting activity
CN116964045A (zh) 用于治疗与sting活性有关的疾病的草酰胺化合物和组合物
CN117321048A (zh) 用于治疗与sting活性有关的疾病的化合物和组合物
CN118715205A (zh) 用于治疗与sting活性相关的病症的化合物和组合物
JP2024532798A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
CN118119595A (zh) 用于治疗与sting活性有关的疾病的化合物和组合物
HK40107251A (zh) 用於治疗与sting活性有关的疾病的化合物和组合物
HK40048003B (zh) 用於治疗与sting活性有关的疾病的化合物和组合物
HK40048005A (en) Compounds and compositions for treating conditions associated with sting activity
HK40048003A (en) Compounds and compositions for treating conditions associated with sting activity

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20250205

Address after: Basel, SUI

Applicant after: NOVARTIS PHARMA AG

Country or region after: Switzerland

Address before: U.S.A.

Applicant before: Afumdeyou Co.,Ltd.

Country or region before: U.S.A.

GR01 Patent grant
GR01 Patent grant